Abstract:Key PointsMany cell cycle proteins are overexpressed or overactive in human cancers, in particular, D-type and E-type cyclins, cyclin-dependent kinases (CDK4, CDK6 and CDK2), Polo-like kinase 1 (PLK1) and Aurora kinases (Aurora A and Aurora B). In transgenic mice, overexpression of several of these cell cycle proteins induces or contributes to tumorigenesis, revealing their prominent oncogenic roles.Some of these cell cycle proteins are also required for tumorigenesis, and their ablation in mice impairs tumour formation induced by specific genetic lesions or by carcinogen treatment, as demonstrated for several cyclins (D1, D2 and D3) and CDKs (CDK4, CDK6, CDK2 and CDK1), as well as for checkpoint kinase 1 (CHK1). Importantly, in some cases the continued presence of a cell cycle protein has also been shown to be required for tumour maintenance and progression, for example, for cyclin D1, cyclin D3 and CDK4, thereby providing a clear rationale for targeting these proteins in cancer treatment.Kinases involved in cell cycle checkpoint function such as CHK1 and WEE1 also constitute potential therapeutic targets. Their inhibition compromises checkpoint function, causes excessive DNA damage and eventually leads to apoptosis, particularly in cells with compromised p53 function.CDK4/6-selective inhibitors, such as palbociclib, ribociclib and abemaciclib, have shown significant benefits in clinical studies, particularly in breast cancer, but also in non-small-cell lung cancer, melanoma and head and neck squamous cell carcinoma. Importantly, following demonstration of a substantial improvement in progression-free survival, combination of palbociclib and letrozole received accelerated approval for first-line treatment of patients with advanced ER+HER2− breast cancer.Inhibitors of PLK1, such as rigosertib and volasertib, have also shown encouraging results in clinical phase II/III studies for patients with myelodysplastic syndromes and acute myelogenous leukaemia, respectively, and several phase III trials are currently ongoing.Compounds targeting Aurora A, particularly alisertib, have been extensively studied in preclinical models and demonstrated synergy with many other targeted therapies, leading to tumour regression in various cancer models. Moreover, clinical studies revealed encouraging activity of alisertib in peripheral T cell lymphoma, non-Hodgkin lymphoma, non-small-cell lung cancer and breast cancer.

Cell cycle kinases in osteosarcoma: potential for therapeutic intervention.

Polo-like kinase 1 as a potential therapeutic target for osteosarcoma.

Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma.

Aurora B Kinase As a Novel Molecular Approach for Osteosarcoma Therapy

Comprehensive analysis of the expression and prognosis for cyclin-dependent protein kinase family in osteosarcoma

PI3K/Akt signaling in osteosarcoma

Targeting the Anaphase-Promoting Complex/cyclosome (APC/C)- Bromodomain Containing 7 (BRD7) Pathway for Human Osteosarcoma

New molecular insights into osteosarcoma targeted therapy

Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma

Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma

Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma.

Cyclovirobuxine D Inhibits the Growth of Osteosarcoma Cells Through the Induction of Autophagy Flux Arrest by Promoting Lysosomal Acidification

Molecular Biology of Osteosarcoma

Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma

The role of programmed cell death in osteosarcoma: From pathogenesis to therapy

Cyclin-Dependent Kinase 7 (Cdk7) Is An Emerging Prognostic Biomarker And Therapeutic Target In Osteosarcoma

Molecular targeted therapy of osteosarcoma and related clinical

Cell cycle proteins as promising targets in cancer therapy

CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma

Translational biology of osteosarcoma

Osteoclasts in Osteosarcoma: Mechanisms, Interactions, and Therapeutic Prospects